undamentalytics Newsletter
Sign in

Neuronetics, Inc. income statement

In fiscal 2025, Neuronetics, Inc. reported revenue of $149m, up 99.2% on the year before, operating income of −$31.4m (a -21.1% margin) and net income of −$39.0m, or −$0.59 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue344053634955657175149155
Cost of revenue710121512121520217779
Gross profit2831404738445052547276
Research and development88814989101376
Selling and marketing2228384333385047464744
General and administrative79141718262625305049
Operating income−9−14−20−27−22−28−35−31−35−31−23
Interest expense23445445789
Income before tax−11−16−24−29———————
Net income−11−16−24−29−27−31−37−30−44−39−30
Diluted EPS−$19.24−$21.59−$0.67−$0.79−$0.73−$0.61−$0.69−$0.53−$0.69−$0.59−$0.44
Diluted shares (average)——36m37m38m51m54m57m63m66m70m
EBITDA−9−13−19−26−21−27−33−29−32−28−20

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: INFU vs STIMRXST vs STIMBBNX vs STIMLAKE vs STIM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuronetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuronetics, Inc.